Apimeds Pharmaceuticals US (APUS) Operating Income (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Operating Income of -$7.0 million for Q4 2025, down 2454.32% on a YoY basis from $299026.3 in Q4 2024, and down 281.73% quarter-over-quarter from -$1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Operating Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Operating Income for 2 years, with the latest figure at -$7.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Operating Income fell 2454.32% year-over-year to -$7.0 million; the trailing twelve-month figure through Dec 2025 stood at -$11.9 million (down 834.25% YoY), and the FY2025 full-year result was -$11.9 million, down 834.25% from the prior year.
  • Operating Income for Q4 2025 stood at -$7.0 million, down from -$1.8 million in the prior quarter.
  • The five-year high for Operating Income was -$271726.0 in Q1 2024, with the low at -$7.0 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 652.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 833.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 325.80 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 14.03 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 193.40 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 307.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -48.28 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -78.32 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 81.33 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - -7.04 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.04 Mn
Sep 30, 2025 -1.84 Mn
Jun 30, 2025 -2.66 Mn
Mar 31, 2025 -364,368.00
Dec 31, 2024 -275,613.00
Sep 30, 2024 -299,999.00
Jun 30, 2024 -427,757.00
Mar 31, 2024 -271,726.00